Bismuth-Based Quadruple Therapy for Clarithromycin-Resistant Helicobacter pylori Infection: Effectiveness and Cost-Efficiency

Gut Liver. 2022 Nov 15;16(6):807-808. doi: 10.5009/gnl220414.

Authors

Moon Won Lee¹, Gwang Ha Kim¹

Affiliation

¹ Department of Internal Medicine, Pusan National University College of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan, Korea.

No abstract available

Publication types

Editorial
Comment

MeSH terms

Amoxicillin / therapeutic use
Anti-Bacterial Agents / therapeutic use
Bismuth / therapeutic use
Clarithromycin / therapeutic use
Drug Therapy, Combination
Helicobacter Infections* / drug therapy
Helicobacter pylori*
Humans
Proton Pump Inhibitors / therapeutic use
Treatment Outcome

Substances

Bismuth
Clarithromycin
Amoxicillin
Anti-Bacterial Agents
Proton Pump Inhibitors